Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Necrotizing Enterocolitis
Interventions
DRUG

hydrocortisone

Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.

DRUG

placebo

Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.

Trial Locations (2)

60201

NorthShore University HealthSystem, Evanston

Unknown

University of Chicago Comer Childrens Hospital, Chicago

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Chicago

OTHER

lead

Endeavor Health

OTHER